Press "Enter" to skip to content

Why monoclonal antibodies are expensive and hard to make in the fight against COVID-19.

Monoclonal antibody treatment for COVID-19, like the one from Regeneron, isn’t a traditional drug. It’s tough to make in the lab.


Source: The Daily News

Be First to Comment

    Leave a Reply

    %d bloggers like this: